PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-15.30%
Both companies show declining cash positions (-15.30% vs TRVN's -8.36%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-15.30%
Cash + STI yoy 1.25-1.5x TRVN's -13.68%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.91%
1.25-1.5x TRVN's -14.22%. Bruce Berkowitz checks if strong current asset growth is used effectively.
-12.74%
≥ 1.5x TRVN's -7.91%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Higher Other Non-Current Assets Growth compared to TRVN's zero value, indicating worse performance.
-1.64%
Below half of TRVN's -5.90%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
1.25-1.5x TRVN's -13.67%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
72.22%
Less than half of TRVN's -20.13%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.94%
Less than half of TRVN's 4296.55%. David Dodd sees fewer expansions in other current obligations.
32.21%
Above 1.5x TRVN's 13.89%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.21%
Above 1.5x TRVN's 1.76%. Michael Burry sees a potential leverage warning sign.
0.06%
Higher Common Stock (Book Value) Growth compared to TRVN's zero value, indicating worse performance.
-3.27%
0.75-0.9x TRVN's -4.29%. Bill Ackman questions if competitor reinvests profits more robustly.
0.51%
Less than half of TRVN's -100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-24.85%
Similar yoy to TRVN's -26.01%. Walter Schloss sees parallel net worth trends.
-15.58%
1.25-1.5x TRVN's -13.67%. Bruce Berkowitz checks if expansions are well-justified by ROI.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.30%
Similar yoy changes to TRVN's 15.87%. Walter Schloss sees parallel net leverage strategies.